Parallel efforts are refining highly selective RET inhibitors with favourable paediatric safety profiles and negligible off-target VEGFR blockade, a characteristic that may attenuate dose-limiting hypertension and thrombotic events often observed with multikinase agents (41). The gene discussed is RET; the disease is hypertensive disorder.